FI
VIRX

Fosun International’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Fosun International’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,714
Closed -$863K – 328
2019
Q1 		$863K Buy
+20,714
New +$469K 0.05% 175

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fosun International's VIRX Position: Q2 2019 in Review

Fosun International sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2019, closing a stake of 20,714 shares — an estimated $863K sold.

Fosun International first reported a position in VIRX in Q1 2019 and held it in 1 quarter. The position peaked at $863K in Q1 2019. 45 funds tracked by Wall St. Rank hold VIRX as of Q2 2019.

  • Fosun International reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Fosun International sold 20,714 Viracta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $863K.
  • Fosun International first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Fosun International's Viracta Therapeutics, Inc. Common Stock position peaked at $863K in Q1 2019.
  • 45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Fosun International's 13F filing for Q2 2019, filed 12 Aug 2019.